[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE60326819D1 - Verfahren zur herstellung von inhibitoren der hmg-coa-reduktase - Google Patents

Verfahren zur herstellung von inhibitoren der hmg-coa-reduktase

Info

Publication number
DE60326819D1
DE60326819D1 DE60326819T DE60326819T DE60326819D1 DE 60326819 D1 DE60326819 D1 DE 60326819D1 DE 60326819 T DE60326819 T DE 60326819T DE 60326819 T DE60326819 T DE 60326819T DE 60326819 D1 DE60326819 D1 DE 60326819D1
Authority
DE
Germany
Prior art keywords
hmg
inhibitors
preparation
sub
coa reductase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60326819T
Other languages
English (en)
Inventor
Murat Acemoglu
Bernhard Riss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of DE60326819D1 publication Critical patent/DE60326819D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60326819T 2002-01-31 2003-01-30 Verfahren zur herstellung von inhibitoren der hmg-coa-reduktase Expired - Lifetime DE60326819D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35378702P 2002-01-31 2002-01-31
PCT/EP2003/000954 WO2003064392A1 (en) 2002-01-31 2003-01-30 Process for the manufacture of hmg-coa reductase inhibitors

Publications (1)

Publication Number Publication Date
DE60326819D1 true DE60326819D1 (de) 2009-05-07

Family

ID=27663254

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60326819T Expired - Lifetime DE60326819D1 (de) 2002-01-31 2003-01-30 Verfahren zur herstellung von inhibitoren der hmg-coa-reduktase

Country Status (23)

Country Link
US (2) US7371865B2 (de)
EP (1) EP1472228B1 (de)
JP (1) JP4524111B2 (de)
KR (1) KR20040081161A (de)
CN (1) CN1305853C (de)
AT (1) ATE426594T1 (de)
AU (1) AU2003226971B2 (de)
BR (1) BR0307303A (de)
CA (1) CA2472776C (de)
CO (1) CO5601005A2 (de)
DE (1) DE60326819D1 (de)
EC (1) ECSP045214A (de)
ES (1) ES2323267T3 (de)
HK (1) HK1070651A1 (de)
IL (1) IL162980A (de)
MX (1) MXPA04007396A (de)
NO (1) NO327091B1 (de)
NZ (1) NZ534232A (de)
PL (1) PL370658A1 (de)
PT (1) PT1472228E (de)
RU (1) RU2299196C2 (de)
WO (1) WO2003064392A1 (de)
ZA (1) ZA200405322B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2513837A1 (en) * 2003-02-12 2004-08-26 Paul Adriaan Van Der Schaaf Crystalline forms of pitavastatin calcium
CN100408562C (zh) * 2003-04-24 2008-08-06 大赛璐化学工业株式会社 (3r,5s,6e)-7-[2-环丙基-4-(4-氟苯基)喹啉-3-基]-3,5-二羟基-6-庚烯酸乙酯的制备方法
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
EP1817027A2 (de) * 2004-09-27 2007-08-15 Ranbaxy Laboratories Limited Verfahren zur herstellung von enantiomerisch reinem fluvastatinnatrium und einer neuen polymorphen form davon
HUE027872T2 (en) * 2006-05-03 2016-11-28 Msn Laboratories Private Ltd A novel process for statins and their pharmaceutically acceptable salts
ES2567171T3 (es) * 2006-10-09 2016-04-20 Msn Laboratories Private Limited Nuevo procedimiento para la preparación de estatinas y sus sales farmacéuticamente aceptables
EP2062903A1 (de) * 2007-04-18 2009-05-27 Teva Pharmaceutical Industries Ltd. Statin-Zwischenprodukte und Verfahren zur Herstellung von Statine
JP2010533188A (ja) * 2007-07-12 2010-10-21 テバ ファーマシューティカル インダストリーズ リミティド ロバスタチン中間体及びその製法
WO2010089770A2 (en) * 2009-01-19 2010-08-12 Msn Laboratories Limited Improved process for the preparation of highly pure (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxy-6(e)-heptenoic acid and pharmaceutically acceptable salts thereof
KR101160152B1 (ko) * 2009-02-24 2012-06-27 한미사이언스 주식회사 스타틴 화합물 또는 그 염의 신규 제조방법, 및 이에 사용되는 중간체 화합물
US8987444B2 (en) 2010-01-18 2015-03-24 Msn Laboratories Private Limited Process for the preparation of amide intermediates and their use thereof
JP2013519666A (ja) * 2010-02-23 2013-05-30 カディラ・ヘルスケア・リミテッド Ｈｍｇ−ｃｏａレダクターゼ阻害剤およびその調製のための方法
EP2383260A3 (de) 2010-04-30 2011-12-28 Dipharma Francis S.r.l. Verfahren zur Herstellung von Statine
WO2011141934A1 (en) 2010-05-13 2011-11-17 Matrix Laboratories Ltd. An improved process for the preparation of an intermediate of hmg-coa reductase inhibitors
JP5822169B2 (ja) * 2010-07-01 2015-11-24 ユーハン・コーポレイションＹＵＨＡＮ Ｃｏｒｐｏｒａｔｉｏｎ ＨＭＧ−ＣｏＡ還元酵素阻害剤及びその中間体の製造方法
US8912333B2 (en) * 2010-11-12 2014-12-16 Hetero Research Foundation Polymorphs of pitavastatin calcium
JP6181063B2 (ja) 2011-11-28 2017-08-16 マイラン ラボラトリーズ リミテッドＭｙｌａｎ Ｌａｂｏｒａｔｏｒｉｅｓ Ｌｉｍｉｔｅｄ ＨＭＧ−ＣｏＡレダクターゼ阻害剤の中間体の新規な製造方法
CN103288871A (zh) * 2012-02-28 2013-09-11 浙江京新药业股份有限公司 一种制备二羟基酸HMG-CoA还原酶抑制剂用的中间体及其制备方法和应用
ITVI20130039A1 (it) 2013-02-20 2014-08-21 F I S Fabbrica Italiana Sint I S P A Processo per la preparazione di intermedi chiave per la sintesi di statine
CN103172656B (zh) * 2013-04-02 2015-07-08 浙江科技学院 3-二甲基叔丁基硅氧基戊二酸酐的合成工艺
CN111518035A (zh) * 2020-06-18 2020-08-11 安徽鼎旺医药有限公司 一种瑞舒伐他汀叔丁胺盐及其制备方法
CN113683539B (zh) * 2021-09-23 2023-05-16 上海裕兰生物科技有限公司 一种聚酮中间体的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354772A (en) * 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4650890A (en) * 1984-04-03 1987-03-17 Sandoz Corp. Preparation of olefinic compounds and intermediates thereof
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
CA1336714C (en) 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
US4804770A (en) * 1988-04-29 1989-02-14 E. R. Squibb & Sons, Inc. Process for preparing a keto-phosphonate intermediate useful in preparing HMG-CoA reductase inhibitors
DE3911064A1 (de) * 1989-04-06 1990-10-11 Bayer Ag Substituierte 1,8-naphthyridine
US5049577A (en) * 1990-01-29 1991-09-17 E. R. Squibb & Sons, Inc. 2-pyrrolidone substituted dihydroxy alkanoic, alkenoic and alkynoic acids, compositions and HMG-CoA reductase inhibition therewith
JP3528186B2 (ja) 1991-06-24 2004-05-17 日産化学工業株式会社 光学活性キノリンメバロン酸のジアステレオマー塩
US6528661B2 (en) * 2000-11-16 2003-03-04 Teva Pharmaceutical Industries Ltd. Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide
KR100883874B1 (ko) * 2001-02-02 2009-02-17 미쯔비시 가가꾸 가부시끼가이샤 (3ｒ,5ｓ)-(ｅ)-7-[2-시클로프로필-4-(4-플루오로페닐)-퀴노린-3-일]-3,5-디하이드록시헵트-6-엔산 에스테르류의 제조방법
ATE509914T1 (de) * 2001-11-14 2011-06-15 Nissan Chemical Ind Ltd Verfahren zur herstellung optisch aktiver oxoheptensäureester
US6835838B2 (en) * 2002-01-28 2004-12-28 Novartis Ag Process for the manufacture of organic compounds
GB0210234D0 (en) * 2002-05-03 2002-06-12 Novartis Ag Process for the manufacture of organic compounds

Also Published As

Publication number Publication date
ECSP045214A (es) 2004-09-28
NZ534232A (en) 2006-03-31
NO20043611L (no) 2004-08-30
BR0307303A (pt) 2005-01-11
EP1472228B1 (de) 2009-03-25
CN1305853C (zh) 2007-03-21
ES2323267T3 (es) 2009-07-10
RU2004126442A (ru) 2005-06-10
US20050070605A1 (en) 2005-03-31
ZA200405322B (en) 2005-07-27
NO327091B1 (no) 2009-04-20
CO5601005A2 (es) 2006-01-31
CA2472776C (en) 2011-01-25
IL162980A (en) 2010-02-17
US20080182873A1 (en) 2008-07-31
ATE426594T1 (de) 2009-04-15
CN1622937A (zh) 2005-06-01
JP4524111B2 (ja) 2010-08-11
HK1070651A1 (en) 2005-06-24
CA2472776A1 (en) 2003-08-07
US7371865B2 (en) 2008-05-13
WO2003064392A1 (en) 2003-08-07
PL370658A1 (en) 2005-05-30
EP1472228A1 (de) 2004-11-03
JP2005520814A (ja) 2005-07-14
PT1472228E (pt) 2009-06-24
MXPA04007396A (es) 2004-10-11
RU2299196C2 (ru) 2007-05-20
AU2003226971B2 (en) 2006-11-30
KR20040081161A (ko) 2004-09-20

Similar Documents

Publication Publication Date Title
DE60326819D1 (de) Verfahren zur herstellung von inhibitoren der hmg-coa-reduktase
IL177537A (en) Viral polymerase inhibitors, and pharmacological compounds containing them
EP2292209A3 (de) Stabile pharmazeutische Zusammensetzung enthaltend ein Pyrimidin-sulfamid
EP1338595A3 (de) Xanthin-Derivate als DPP-IV-Inhibitoren
EP1604989A8 (de) DPP-IV-Hemmer
MXPA05012268A (es) N-arilsulfonilpiperidinas enlazadas como inhibidores de la gamma-secretasa.
NO20062656L (no) Fremgangsmate for fremstilling av statiner
EP2308828A3 (de) CaSR-Antagonist
DE602004005323D1 (de) Azidfreies verfahren zur herstellung von 1,2-diaminoverbindungen
EP1975164A3 (de) Octahydrobenzimidazolon-Verbindungen als Analgetika
DE60104825D1 (de) Verfahren zur herstellung von 6-substituierten (s)-nikotin-derivaten und zwischenverbindungen
MXPA05013584A (es) Compuesto amina terciaria ciclica.
ATE429429T1 (de) Pharmazeutisches verfahren und damit hergestellte verbindungen
EA200301120A1 (ru) Цитрат 5,8,14-триазатетрацикло (10.3.1.0.0)-гексадека-2 (11),3,5,7,9-пентаена
MXPA04000357A (es) COMPUESTO QUE CONTIENE AMIDA Y TIENE UNA MEJOR SOLUBILIDAD, Y MeTODO PARA MEJORAR LA SOLUBILIDAD DE UN COMPUESTO QUE CONTIENE AMIDA.
MY138826A (en) 2,7-substituted indoles
EP2266971A3 (de) HIV-Protease inhibierende Verbindungen
WO2004111008A3 (en) Use of a compound of formula i for making a pharmaceutical composition
DE60228724D1 (de) Verfahren zur herstellung von beraprost und dessen salzen
DE60101786D1 (de) Verfahren zur herstellung von citalopram
EP2279741A3 (de) Caprolactame und deren Verwendung als entzündungshemmende Mittel
MY129094A (en) Condensed polycyclic compounds
EP1310490A4 (de) Gpr14-antagonisten
EP1199308A3 (de) Herstellungsverfahren für Imidazodiazepine-Zwischenprodukte
ATE496038T1 (de) Verfahren zur herstellung von quetiapin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition